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Summary. Background and aim of the work: The Lynch Syndrome (LS) is associated with germline mutations 
in one of the MisMatch Repair (MMR) genes, including MLH1, MSH2, MSH6, PMS2, MLH3 and MSH3. 
The molecular characterization of mutations in these MMR genes facilitates the pre-symptomatic diagnosis 
of subjects at risk to develop a colon cancer or a cancer LS-related. Methods: DHPLC and direct sequencing 
were performed for the mutation detection analysis. Results: In this study, we identified a novel frame shift 
mutation, the named is c.170delT in MSH2 gene that determined a premature stop codon and consequently, 
the formation of a truncated protein (p. Val56Glyfs*7). This is a novel mutation, as it has not been reported 
before in the international scientific literature. This mutation was found in two subjects (father and son) 
belonging to a LS family. However, they showed a different phenotype disease. Conclusion: In this study, we 
identified and characterized a novel MSH2 mutation; moreover, this study reaffirmed the importance of ge-
netic testing in Lynch syndrome. 
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Introduction
Colorectal cancers are frequent causes of death in 
the world (1). Although most cases are sporadic, up to 
5-6% develops in the context of gastrointestinal he-
reditary syndromes (2). Some syndromes are inherited 
in mendelian manner as they are due to alteration in 
a specific gene. These syndromes include familial ad-
enomatous polyposis (FAP), hereditary non-polyposis 
colorectal cancer (HNPCC), PTEN hamartoma tu-
mor syndrome (PHTS) and Peutz-Jeghers (3-7). With 
genetic testing for detection the mutation responsible 
of disease, it is possible to make differential diagnosis 
among these syndromes and to perform a pre-symp-
tomatic diagnosis identifying the carriers of specific 
mutation in family at high colon cancer risk. Thus, 
DNA testing may change the individual’s presumed 
risk status and affect decision-making by patients and 
their physicians regarding surveillance and manage-
ment (8,9).
The HNPCC, also known as Lynch syndrome 
(LS) is inherited as dominant autosomal. The Lynch 
Syndrome is characterized by onset of colon cancer on 
average around 45 years as well as an increased risk 
of developing extra-colonic tumors such as endome-
trial cancer, ovarian, stomach, urinary and biliary tract 
(10,11). Identification of families affected by LS oc-
curs by the Amsterdam Criteria (AC) and Bethesda 
guidelines (BG) (12, 13). LS is associated with mu-
tations in MisMatch Repair (MMR) genes. Most of 
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mutations were found in the MLH1 and MSH2 genes 
that account for about 50% and 40% respectively of all 
mutations reported; only 10% of mutations were iden-
tified in the MSH6 and 5% in PMS2 (14, 15); a low 
percentage of mutations were identified in MLH3 (16) 
gene and only one variant in MSH3 gene was associat-
ed with LS phenotype (17). Mutations are distributed 
heterogeneously along each MMR gene, denoting the 
absence of “hot spot” mutations. The most frequently 
detected pathogenetic variants in MLH1 and MSH2 
are small insertions/deletions or large genetic rear-
rangements (large deletions/insertions) that, at protein 
level, result in premature stop codon formation (18-
20). Each mutation in one MMR genes is considered 
pathogenetic if determines the loss or  malfunction of 
MMR complex. The loss of function of one MMR 
protein prevents to repair’s complex to work properly 
and this determines a genetic instability known as mi-
crosatellite instability (MSI) at somatic level (21). At 
somatic level the MSI is detectable by immunohisto-
chemistry (IHC) analysis (22). 
In this study, we reported a novel frameshift muta-
tions in MSH2 gene that was identified in two affected 
subjects belonging to a family with Lynch syndrome.
Materials and methods
Patients
Our probands are a 20-year-old male (n. 1440) 
and his father with age of 49 years (n. 1439). The first 
developed a left colon cancer and two dysplastic ad-
enoma at 19 years of age, while his father developed 
a left colon cancer at 44 years of age. The probands’s 
family history was also positive for colorectal and 
extra-colonic cancer. A detailed pedigree is shown in 
Figure 1.
Furthermore, as negative controls we collected 
100 healthy samples from Clinical Department of 
Laboratory Medicine of our Hospital (Federico II of 
Naples).
Sample from our patient was collected after being 
granted authorisation from our local Ethic Committee 
“Comitato etico per le attività Biomediche - Carlo Ro-
mano” of the University of Naples Federico II (proto-
col number 120/10). Once the authorisation has been 
obtained the study has received ethical approval, and 
participant’ informed and written consent has been 
obtained.
Mutation analysis: Isolation of genomic DNA,
amplification, dHPLC and sequencing 
The genomic DNA was extracted from peripheral 
blood lymphocytes. Total genomic DNA was extract-
ed from 4 mL peripheral blood lymphocytes using a 
BACC2 Nucleon Kit (Amersham Life Science). 
All MLH1 and MSH2 exons were amplified, in-
cluding intron-exon boundaries, on DNA extracted 
from blood lymphocytes of our patient, using cus-
tomized primer sets (available on request). Prior to 
dHPLC analysis, the PCR products were run on an 
1-2% agarose gel to check for unspecific amplicons. 
A Transgenomic Wave DNA Fragment Analysis Sys-
tem (3500 HT) was used to perform dHPLC analysis 
(Transgenomic Inc., Omaha, Nebraska, USA) using 
personal methods, available on request; subsequently, 
genomic DNA was re-amplified and sequenced in 
both the forward and reverse directions using an ABI 
3100 Genetic Analyser (Applied Biosystems, Foster 
City, Ca., USA). 
Results
In this study, we have analyzed the DNA of our 
patients, n.1439 and n.1440. All MLH1, MSH2, ex-
ons were analysed by DHPLC; subsequently, we only 
sequenced exonic fragments that showed an abnormal 
chromatogram. In this manner, we identified a novel 
mutation in the MSH2 gene that determined a nu-
cleotide deletion (T) in position c.170. This mutation 
that is named c.170delT, determined a frameshift with 
premature stop codon and consequently, the formation 
of a truncated protein (p. Val56Glyfs*7). This mutation 
has not been reported before in the international data-
base of INSIGHT-Group (20) and it was not detected 
in 100 healthy controls analyzed. Therefore, this muta-
tion is considered as pathogenetic. No large rearrange-
ments in MLH1 and MSH2 genes were identified in 
our patients. 
B. Cudia, A.I. Lo Monte, R. Liccardo, et al.128
Discussions
In this study, we report the results of the detection 
mutation analysis of a family with Lynch Syndrome. 
The mutation identified, the c.170delT is a novel 
frameshift variant that causes the formation of a pre-
mature stop codon and hence of a truncated protein. 
Two subjects belonging to LS family were to carrier of 
this novel mutation in the MSH2 gene. Both subjects 
showed a MSI-H status on DNA extracted from tu-
moral tissue embedded paraffin and loss of expression 
of MSH2 on tissue detected by immunohistochemistry 
analysis (data not shown). Therefore, the MSH2 muta-
tion c.170delT is, surely responsible of LS-phenotype 
in these patients and likely, in remaining affected sub-
jects of family. These patients (father and son) were 
both affected by left colon cancer; however, the father, 
a 49-year-old patient developed an adenocarcinoma in 
left colon diagnosed at the age of 44 years and, the son 
developed an adenocarcinoma in left colon diagnosed 
at the age of 20 years. Hence, this novel mutation was 
associated with a phenomenon of generational antici-
pation in this family (23). So far, no clear correlation 
genotype-phenotype were described for LS families 
Figure 1. A. and B. Chromatogram and electropherogram showing the novel mutation identified in exon 1 of MSH2 gene, c.170delT; 
C. Family pedigrees of our patients with a novel MSH2 gene mutation. Symbols and abbreviations used are denoted as fellow: arrows, 
index case; black symbol, colorectal cancer or tumors associate with LS; Co, colon cancer; St, stomach cancer; Lym, lymphoma; Sem, 
seminoma. Number next to diagnosis denote age at onset
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(24), therefore, we could only speculate that modifier 
genes could be responsible of this generational antici-
pation (25). Moreover, this family’s history was also 
positive for colorectal and extra-colonic cancer, Fig. 
1. In particular, the cases of extracolic cancers were a 
lynphoma and a seminoma onset simultaneously, in a 
young relative of our probands (II-1, Fig. 1) and these 
two infrequent cancers in LS (11). Unfortunately, we 
were not able to performed genetic testing for this sub-
ject due to his limited availability. 
In conclusion, this study remarks the phenotypic 
heterogeneity of LS and it enlarges the spectrum of 
MSH2 mutations. Moreover, this study reaffirms the 
importance to identify pathogenic mutations in LS 
families to facilitate pre-symptomatic diagnosis order 
to personalize the program of endoscopic surveillance 
for mutation carrier subjects, in particular in LS fami-
lies whose the phenomenon of generational anticipa-
tion is present.
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